Table 3.
Safety parameters
| Compound | Aleglitazar | GFT505 | K-877 | Fenofibrate | ||
|---|---|---|---|---|---|---|
|
Study |
SYNCHRONY[43,44] |
S1[48] |
S2[48] |
K-877 P2[50] |
FIELD[12] |
K-877[50] |
|
Dosage |
150 μg QD |
80 mg QD |
80 mg QD |
100 μg BID |
200 mg QD |
100 mg QD |
|
Time point (weeks) |
16 |
4 |
4 |
12 |
16 |
12 |
| ALT (UI/L) |
NA |
−7.1 |
−2.1 |
−7.6 |
NA |
−4.2 |
| γGT (UI/L) |
NA |
−11.0 |
−6.0 |
−24.6 |
NA |
0.0 |
| Serum creatinine (mg/dL) |
NA |
0.038* |
0.057* |
0.013 |
NA |
0.086 |
| Homocysteine (nmol/mL) | NA | 1.71 | −0.8 | 0.16 | NA | 2.21 |
ALT alanine aminotransferase; BID twice-daily; γGT γ-glutamyl transpeptidase; NA not available; QD once daily.
Data are expressed as mean changes from baseline.
*To convert from μmol/L to mg/dL, values were divided by 88.4.